Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19331872 | 1.00 | MEN1 (0.42) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL19331833 | 1.00 | MEN1 (0.42) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL30803371 | 0.92 | ESR2 (0.46) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL2558056 | 0.92 | ESR2 (0.46) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL14954612 | 0.92 | ESR2 (0.46) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL20660282 | 0.89 | GRM5 (0.49) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL20660281 | 0.89 | GRM5 (0.49) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL344121 | 0.85 | USP2 (0.41) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL99227 | 0.82 | GRM5 (0.53) | MEN1KMT2AALDH1A1MAPTCTSK | |
| SCHEMBL991492 | 0.82 | ESR2 (0.45) | MEN1KMT2AALDH1A1MAPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3492471-B1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX INC (CN) | 2020-12-02 | — | — | EP | disclosed |
| CN-109851620-B | Fused bicyclic compounds for inhibiting tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-3492471-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | LCK, BTK, BRAF | MEN1 4809/4885KMT2A 3118/4885ALDH1A1 3535/4885 |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | LCK, BTK, LYN | MEN1 4493/4885KMT2A 1821/4885ALDH1A1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.